Sobi expands haemophilia B development portfolio

Swedish Orphan Biovitrum (Sobi) has elected to add a novel product candidate (rFIXFc-XTEN) for the potential treatment of haemophilia B to the company’s collaboration agreement with Bioverativ.

Sobi said that it has the right to include the rFIXFc-XTEN fusion molecule into its collaboration agreement with Bioverativ. By making a one-time payment to Bioverativ Sobi gains an opt-in right to participate in the final development and commercialisation of this product candidate. The opt-in right may be exercised by Sobi in connection with the submission of the marketing authorisation application for rFIXFc-XTEN with the European Medicines Agency.

In September 2014, Sobi elected to add the rFVIIIFc-VWF-XTEN fusion molecule for the potential treatment of haemophilia A to its collaboration agreement with Bioverativ.